Last reviewed · How we verify
ES014
ES014 is a monoclonal antibody targeting PD-1.
ES014 is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | ES014 |
|---|---|
| Also known as | ES014 for Injection |
| Sponsor | Elpiscience (Suzhou) Biopharma, Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to PD-1, ES014 prevents its interaction with PD-L1, thereby unleashing T-cell mediated immune responses against cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
Key clinical trials
- A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours (PHASE1)
- A Study of ES014 in Subjects With Advanced Solid Tumors (PHASE2)
- A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |